Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...

Regeneron Pharmaceuticals announced that the ... Odronextamab is already approved in the EU under the name Ordspono™ for similar indications. The ongoing clinical development program for ...

Regeneron Pharmaceuticals is taking another ... under the brand name Ordspono for r/r FL and diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...